Australian patient travels 9,000 miles for a cure

March 7, 2019 | Michael Easterling

Australian lobster fisherman David Thompson traveled 9,000 miles for treatment at City of Hope after being diagnosed with Stage 4 oropharyngeal cancer. Given just six weeks to live, he is thriving more than a year after participating in an immunotherapy clinical trial.

Continue Reading

Study explores why glioblastoma affects sexes differently

February 25, 2019 | City of Hope

A nationwide team of researchers that includes City of Hope’s Translational Genomics Research Institute (TGen) has identified molecular differences that explain why men die of glioblastoma, a type of brain cancer, at nearly twice the rate of women.

Vanessa Jonsson, Ph.D.: An engineer tackles CAR T cell therapy

February 13, 2019 | City of Hope

Vanessa Jonsson, Ph.D., focuses on chimeric antigen receptor (CAR) T cell therapy. Using such tools as computational analysis and mathematical modeling, she examines the complex interactions between the tumor, the patient’s immune system and the therapy to learn how the tumor evades the immune response.

Clinical research nurses: ‘Shepherds’ of the CAR T program

January 9, 2019 | Abe Rosenberg

What's it like to work at the center of a true medical and scientific revolution? It's emotional, often overwhelming. But it’s also a place to witness miracles. Such is the life of the clinical research nurses who staff City of Hope's CAR T cell program.

Groundbreaking new CAR T cell trial opens for patients with breast cancer that has spread to the brain

October 30, 2018 | Letisia Marquez

A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants. 

CIRM Awards City of Hope Researchers $3.7 million to Develop Glioblastoma Clinical Trial

September 28, 2018 | Letisia Marquez

California Institute for Regenerative Medicine has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients, which would genetically alter blood stem cells to better tolerate chemotherapy.

A breakthrough treatment for melanoma metastasized to the brain

September 6, 2018 | Maxine Nunes

A remarkable new study, groundwork for which was begun by City of Hope oncologist Kim Margolin, M.D., brings new hope to people with melanoma that has metastasized to the brain.

City of Hope Awarded $3.7 million to Develop Glioblastoma Clinical Trial

June 29, 2018 | Letisia Marquez

California Institute for Regenerative Medicine has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients, which would genetically alter blood stem cells to better tolerate chemotherapy.

Rahul Jandial, M.D., Ph.D.: Pediatric Neurosurgery Humanitarian Missions

March 13, 2018 | Denise Heady

Fourteen years ago, neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., began to travel to underserved countries to perform brain surgeries on disadvantaged children.